AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01429454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Long Chain Fatty Acid
Description: : The Omega-3FA compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
Study NCT01429454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them. The dose will be 2 capsules per day.
Study NCT01481974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil
Description: The Treatment Phase will begin at the initiation of Treprostinil after induction of anesthesia for the transplant surgery and continues throughout the surgery and for approximately a total of 120 hours.~Treatment phase activities include:~• Initiation of Treprostinil after the patient is hemodynamically stable following transplant surgery. (Treprostinil dosing will follow a standard 3 + 3 phase 1 design.
Study NCT03444415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational interviewing in groups
Description: Intervention consists of six 90 minutes workshops, two of those during pregnancy and the other four within the following two years after the birth of the children.
Study NCT03444415 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Parents will receive information about height, weight, and BMI percentile provided by a health professional during usual well child visits
Study NCT04412005 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00403494 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive matching oral Placebo twice daily for 24 weeks.
Study NCT00403494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin Dihydrochloride
Description: Subjects receive 400 mg oral sapropterin dihydrochloride twice daily for 24 weeks.
Study NCT03851094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellth app
Description: The intervention is the use of Restful, the Wellth self-management app. There is no clinical treatment intervention, as all participants will be receiving PAP therapy per standard of care. Restful is a smartphone-based patient engagement tool that utilizes concepts from behavioral economics to help patients improve their adherence to therapy. The intervention includes a financial and social incentive reward program.
Study NCT04121741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Singing with Music Therapist
Description: Music therapy sessions will begin with vocal and breathing warm-up exercises for about 10 minutes. The Music Therapist will play the songs (chosen from a list by the subject) to sing along to and will alter the characteristics of the music (volume, tempo, level of support) to ensure a successful experience for subjects and motivate them to put forth more effort into singing the song. The music therapist will continue to coach throughout the 30-minute session, reminding subjects of strategies practiced and how to implement those strategies while singing. Music therapy sessions will be led by Erica Flores, MT-BC, WMTR, Owner of Healing Harmonies Music Therapy, or a member of her team. Erica and her team of MTs were trained in Neurological Music Therapy.
Study NCT04121741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Singing with Guided Video
Description: The videos will include a vocal warm-up (10 minutes long). The subject will then have the option to select and sing two songs (10 minutes each), with offerings in four music genres including Folk, Pop, Country, and a Hymn. Each piece will vary in tempo, melodic contour, and rhythm. The total duration of singing via this format will be 30 minutes.
Study NCT04121741 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Arm
Description: 30 minute rest period, no singing will take place during this arm. During this rest period a member of the study team will assist the subject in a hearing test using headphones, a tablet, and a trumpet app. This is done to asses the current hearing level of the subject.
Study NCT01271244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10-20mg daily for 12 weeks
Study NCT00986752 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting (Smart Stent)
Description: Nitinol stent
Study NCT00986752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stenting (Smart Stent)
Description: Nitinol stent
Study NCT00986752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stenting after PEB (Smart Stent, Invatec)
Description: Stenting (nitinol stent) after dilation with Paclitaxel-eluting balloon (PEB).
Study NCT00986752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atherectomy (SilverHawk device)
Description: Atherectomy
Study NCT03246750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B-MAD chemotherapy
Description: B-MAD chemotherapy
Study NCT03490032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]-PSMA-R2
Description: radio-labelled PSMA ligand
Study NCT00253266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Venlafaxine
Description: Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)
Study NCT00253266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)
Study NCT00253266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine up to 200 mg/d for four weeks
Study NCT01040312 — intervention group
Intervention type: DRUG
Intervention: CPT-11
Description: CPT-11 blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.
Study NCT01040312 — intervention group
Intervention type: DRUG
Intervention: Platinum analogues
Description: Platinum compounds produce changes in DNA structure, which causes cancer cell death (apoptosis). They are typically used alone or in combination with other chemotherapy drugs.
Study NCT04016558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TunedIn
Description: TunedIn utilizes emotion regulation-based strategies to help participants observe that how they feel affects what they do regarding diabetes management. Participants will attend two highly interactive group workshops (6 hours followed by 2 hours) facilitated by a psychologist or social worker experienced in diabetes. Each will identify and discuss common emotional responses related to blood glucose management (e.g., over-reacting, avoiding, and lack of mindfulness).~Between the two workshops (two weeks), participants will complete a feeling log to document feelings, situation/context, and resolution around specific management events. Two individual meetings with the interventionist (30 minutes) will allow participants to identify and address a specific diabetes distress-related problem. Four web-based video group meetings (60 minutes, monthly) will continue to support participants over time.
Study NCT00416975 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: counseling intervention
Description: Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
Study NCT00416975 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: educational intervention
Description: Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
Study NCT00416975 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: evaluation of cancer risk factors
Description: Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
Study NCT04463394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: Vasopressin administered intravenously
Study NCT04016558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FixIt
Description: FixIt combines components of StreamLine and TunedIn to allow participants to explore feelings and expectations alongside the identification of problematic blood glucose patterns. StreamLine will be co-facilitated by a psychologist/social worker experienced in diabetes and a CDE. Participants will attend two group workshops (six hours followed by four hours), separated by two weeks.~Between the two workshops, participants will record their blood glucose data and keep a parallel feeling log to provide context. Four individual meetings with an interventionist (30 minutes) will allow participants to identify and address a specific blood glucose problem and create a plan to address it. Full discussion of diabetes distress-related aspects of the plan will take place to enhance mindfulness and identify typical emotion regulation strategies to ease problem resolution. Three web-based video group meetings (60 minutes, monthly) will continue to support participants over time.
Study NCT01101971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic exam video tutorial
Description: Bryden Magee (Meds 2010) and Dr. Robert Reid created an educational DVD © 2009 that outlines a step-by-step approach to the pelvic exam; utilizing real patient video clips and illustrations. Endorsed by the Association of Professors of Obstetrics and Gynaecology of Canada (APOG), this innovation has been shown to improve both knowledge and confidence in medical students learning these skills (Magee 2009). The video content has been posted on the Queen's streaming server and incorporated into a MEdTech community accessible to all Queen's faculty and students affiliated with the School of Medicine (in MEdTech Central see OBGYN Pelvic Exam Module under community courses).
Study NCT02526823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-CHOP/CHOPE or ABVD chemotherapy regimen
Description: R-CHOP:~Rituximab：375mg/m2，ivgtt，D0； Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CHOPE:~Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~ABVD:~Epirubicin：35 mg/m2，ivgtt，D1、15； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；
Study NCT02526823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CDOP/CDOPE or DBVD chemotherapy regimen
Description: R-CDOP:~Rituximab：375mg/m2，ivgtt，D0； PLD 30-40 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CDOPE:~PLD 30-40 mg/m2，ivgtt，D1； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~DBVD:~PLD 15-20 mg/m2，ivgtt，D1； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；
Study NCT02852395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-48816274
Description: Oral dose; dose range of 5 mg up to 250 mg
Study NCT02852395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose; appearance matched to JNJ-48816274
Study NCT03395704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride Injection, USP, or equivalent
Study NCT03152175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: 1mg / kg of propranolol hydrochloride, oral capsule
Study NCT03152175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1mg / kg of matched placebo, oral capsule
Study NCT02679430 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prostate Arterial Embolization
Description: The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms.
Study NCT02131376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-renorrhaphy
Description: The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
Study NCT02131376 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renorrhaphy
Description: After tumor resection the patient will have both a deep and cortical layer reconstruction
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: busulfan
Description: Busulfan 3.2 mg/kg/day from day -7 to day -4 as standard of care for myeloablative (bone marrow depletion) conditioning at the investigator's discretion
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Busulfan 3.2 mg/kg/day from day -7 to day -4 as standard of care for myeloablative (bone marrow depletion) conditioning at the investigator's discretion
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide
Description: Cyclophosphamide as standard of care for myeloablative conditioning at the investigator's discretion
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cyclophosphamide as standard of care for myeloablative conditioning at the investigator's discretion
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cyclosporin-A
Description: Cyclosporin-A as standard of care for GVHD prophylaxis at the investigator's discretion
Study NCT00513474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporin-A
Description: Cyclosporin-A as standard of care for GVHD prophylaxis at the investigator's discretion
Study NCT03604809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OT Guided Cognitive Interventions
Description: RASS is defined as the level of sedation and agitation of a patient. Cognitive interventions are evidence based strategies that enhance the cognition of patients and include memory training using visual imagery; metacognitive training using self-awareness and self-regulation approaches for recovery of executive functioning; and neuropsychological rehabilitation to help improve cognitive and functional deficits. Interventions will be adjusted according to the RASS score. Cognitive interventions include discussion of patient status and education of family around reorientation, cognitive screening and graded exercises according to patient ability. The deepest levels of sedation and highest levels of agitation will be included in the intervention arm.~Interventions will be provided by the Occupational Therapist; Monday to Friday, BID, 20 minutes per session, for the duration of ICU admission.
Study NCT00606216 — intervention group
Intervention type: PROCEDURE
Intervention: MRI and cognitive evaluation
Description: Patients will undergo a brain MRI study and a brief neuropsychological evaluation, at the time of enrollment for controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients. A follow-up MRI and cognitive evaluation will be performed approximately 12 months after the transplant for patients.
Study NCT00606216 — intervention group
Intervention type: PROCEDURE
Intervention: MRI and cognitive evaluation
Description: Pt will undergo a Magnetic Resonance Imaging (MRI) study of the brain and a brief neuropsychological evaluation, at the time of enrollment for healthy controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients (Baseline/Time 1).
Study NCT00606216 — intervention group
Intervention type: PROCEDURE
Intervention: brain MRI study and a brief neuropsychological evaluation
Description: A brain MRI study and a brief neuropsychological evaluation will be performed at baseline (Time 1). A follow-up MRI and cognitive evaluation will be performed and about 12 months after the baseline for healthy controls
Study NCT01545583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859 intravenous
Description: Administered intravenously
Study NCT01545583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intravenous
Description: Administered intravenously
Study NCT01545583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859 subcutaneous
Description: Administered subcutaneously
Study NCT01545583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo subcutaneous
Description: Administered subcutaneously
Study NCT03466983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside
Description: administered IV
Study NCT03466983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose
Description: administered IV
Study NCT03043443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Natural health product for sleep problems treatment
Study NCT03043443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose containing pills
Study NCT04103164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera excel V™ Laser
Description: The Cutera® excel V laser is manufactured by Cutera, Inc. This laser with 532 nm KTP and 1064 nm Nd:YAG wavelengths has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market the device for use in surgical and aesthetic applications requiring selective photothermolysis of target chromophores in soft tissue 510(k) number 022226. The 532 nm wavelength is indicated for the coagulation and hemostasis of benign vascular and cutaneous lesions in dermatology including, but not limited to, benign vascular lesions like angiomas, hemangiomas, port wine stains, venous anomalies and telangiectasia; benign pigmented lesions like nevi, lentigines, chloasma, café-au-lait; verrucae; skin tags; keratoses; plaques. The Cutera® excel V laser has also obtained the European CE Mark. The system was tested to ensure compliance with federal laser performance standards as applicable.
Study NCT03946956 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prebooking
Description: Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening
Study NCT03946956 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prebooking
Description: Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening
Study NCT03946956 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pictured invitation
Description: Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening
Study NCT03946956 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pictured invitation
Description: Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening
Study NCT04055818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Oral nicotinamide (Vitamin B3) alone compared to THU Decitabine combination
Study NCT03829553 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: 4005 cGy/ 15 fractions / 3 weeks to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67Gy for 4 fractions in patients with intact breast